லிநேபேர்கேற் செல்லுலார் சிகிச்சை ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from லிநேபேர்கேற் செல்லுலார் சிகிச்சை ப்ரோக்ர்யாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In லிநேபேர்கேற் செல்லுலார் சிகிச்சை ப்ரோக்ர்யாம் Today - Breaking & Trending Today

Experimental safety switch reduces severity of CAR-T immunotherapy-related side effects

Experimental safety switch reduces severity of CAR-T immunotherapy-related side effects
UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur. This advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia. It demonstrates a proof-of-principle for possible expanded use of CAR-T immunotherapy paired with the safety switch.
The researchers published their findings in the journal
Blood as an ahead-of-print publication.
With CAR-T therapy, T-cells from a patient s immune system are modified in a manufacturing facility to express part of an antibody that can bind to a surface protein on cancer cells. The modified T-cells, after being infused back into the patient, seek out and attack cancer ce ....

Matthew Foster , Jonathan Serody , Emily Henderson , Lineberger Cellular Immunotherapy Program , Cellular Immunotherapy Program , Lineberger Cellular Therapy Program , School Of Medicine , Bellicum Pharmaceuticals , Lineberger Comprehensive Cancer Center , Comprehensive Cancer Center , Gianpietro Dotti , Cellular Therapy , Acute Lymphoblastic Leukemia , Chimeric Antigen Receptor , Clinical Trial , Immune System , T Cell , மேத்யூ வளர்ப்பு , எமிலி ஹென்டர்சன் , லிநேபேர்கேற் செல்லுலார் நோயெதிர்ப்பு சிகிச்சை ப்ரோக்ர்யாம் , செல்லுலார் நோயெதிர்ப்பு சிகிச்சை ப்ரோக்ர்யாம் , லிநேபேர்கேற் செல்லுலார் சிகிச்சை ப்ரோக்ர்யாம் , பள்ளி ஆஃப் மருந்து , லிநேபேர்கேற் விரிவான புற்றுநோய் மையம் , விரிவான புற்றுநோய் மையம் , செல்லுலார் சிகிச்சை ,

Engineered safety switch curbs severe side effects of CAR-T immunotherapy

E-Mail
IMAGE: Matthew Foster, MD, and his UNC Lineberger colleagues have used an experimental safety switch incorporated as part of a chimeric antigen receptor-modified T cell therapy (CAR-T) for an aggressive form.
view more
Credit: UNC Lineberger Comprehensive Cancer Center
CHAPEL HILL, North Carolina UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur. This advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia. It demonstrates a proof-of-principle for possible expanded use of CAR-T immunotherapy paired with the safety switch. ....

Winnie Lau , Natalie Grover , Robert Hagan , Anastasia Ivanova , Brianne Buchanan , Matthew Foster , Daiichi Sankyo , Kaitlin Morrison , Catherine Cheng , James Coghill , Spencer Laing , Aaron Foster , Paul Armistead , John West , Barbara Savoldo , Jonathan Serody , Lineberger Cellular Immunotherapy Program , Gillings School Of Global Public Health , School Of Medicine , Bellicum Pharmaceuticals , Marsico Lung Institute , University Cancer Research Fund , Merck Inc , Advisory Board Of Kite Pharmaceuticals , Cellular Immunotherapy Program , Lineberger Comprehensive Cancer Center ,